Your session is about to expire
← Back to Search
CAR-T Cell Therapy for Liver Cancer
Study Summary
This trial is testing a personalized cancer treatment, CAR-T cells, to see if it is safe for people with a certain type of liver cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot tolerate the usual chemotherapy for liver cancer.I have hepatitis B, am on antivirals, and my HBV DNA level is below 100IU/mL.I am on blood thinners.I haven't received anti-PD-1 or anti-PD-L1 treatments in the last 8 weeks.My side effects from previous treatments are mild.My condition cannot be cured with surgery or other similar treatments.My liver function is moderately to severely impaired.I have or had an autoimmune disease that could come back.I haven't taken any corticosteroids in the last 14 days.I have a history of seizures.My cancer has spread to my brain.I am 18 years old or older.I am HIV-positive.I can have a biopsy to check my tumor for GPC3.My organs and bone marrow are working well.I agree to use birth control during the study.My tumor shows high GPC3 levels in recent tests.I am fully active or can carry out light work.I do not have any uncontrolled illnesses.I have not been hospitalized in the week before starting treatment.I haven't had any cancer treatment or surgery in the last 4 weeks.My liver cancer worsened after the first treatment or I couldn't tolerate the standard chemotherapy.My condition cannot be cured with surgery or other similar treatments.My heart pumps well and I don't have serious fluid around it.I have not received a live or virus-based vaccine in the last 30 days.I am willing to have a biopsy to check my cancer for GPC3 expression.I am 18 years old or older.I am fully active or can carry out light work.
- Group 1: 1/ Arm 1
- Group 2: 2/ Arm 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How perilous is the application of CAR-T cell therapy for individuals?
"Due to the limited data available, CAR-T cells were given a score of 1 on our safety scale. As this is only a Phase 1 trial, there has been minimal clinical evidence that supports its efficacy and security."
What maladies is CAR-T cell therapy commonly employed to alleviate?
"CAR-T cell therapy is a potent treatment option for multiple sclerosis, in addition to certain lymphomas, leukemias, myelocytic conditions, acute diseases and retinoblastoma."
Have prior experiments featured CAR-T cells?
"At this moment, 889 medical studies are being conducted on CAR-T cell therapy. Of those trials, 161 of them have reached Phase 3 and are located in Philadelphia, Pennsylvania with a total of 28443 operational trial sites available world wide."
Are opportunities for participation in this experiment still available to individuals?
"Yes, according to the clinicaltrials.gov website, this clinical trial is actively searching for participants. This research was initially posted on December 8th 2021 and last updated October 4th 2022. The study requires 38 patients from a single medical centre."
How many applicants are being considered for entry into this research project?
"Affirmative. Clinicaltrials.gov displays that this clinical study, which was initially published on December 8th 2021, is actively searching for participants to enroll in the trial. A total of 38 individuals are required from 1 medical centre."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Most responsive sites:
- National Institutes of Health Clinical Center: < 24 hours
Average response time
- < 1 Day
Share this study with friends
Copy Link
Messenger